Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-06-19
2000-07-04
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544296, 544298, 544319, 544327, A61K 31505, C07D23948, C07D23954
Patent
active
060839554
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to pharmaceuticals, more particularly, novel arylethenesulfonamide derivatives having a high affinity to endothelin receptor, pharmaceutically-acceptable salts thereof and pharmaceutical compositions containing the same, particuarly an antagonist to endothelin receptor.
BACKGROUND ART
Endothelin is an endogenous physiologically active peptide consisting of 21 amino acids and it has been known that, in endothelin, there are three isopeptides of ET-1, ET-2 and ET-3 wherein the amino acid sequences are somewhat different.
Endothelin expresses its physiological action by binding to an endothelin receptor on a target cell membrane. For endothelin receptor, it has been clarified until now that there are at least two subtypes and those subtypes are named ET.sub.A and ET.sub.B, respectively. Those receptors differ in their affinity to endothelin. ET.sub.A receptor has a higher affinity to ET-1 and Et-2 than to ET-3 while ET.sub.B receptor has the affinity of a similar degree to the three types of endothelin.
Endothelin and endothelin receptor are produced and expressed, respectively, in various cells of various organs and varieties of physiological actions which are caused by them have been known. For example, in blood vessel, ET-1 which is produced and secreted in vascular endothelial cells bound ET.sub.A receptor on smooth muscle cells of blood vessel existing near there and contracts the blood vessel strongly and continuously. On the other hand, vascular endothelial cells themselves express ET.sub.B receptor and, when ET-1 is bonded thereto, nitrogen monoxide (NO) is produced and released. Nitrogen monoxide has an action of relaxing the smooth muscle of blood vessel. In fact, when ET-1 is intravenously injected to rat experimentally, long-lasting hypertension is observed after a transient hypotension.
As noted from the physiological action in blood vessel as mentioned above, ET-1 has an aspect as a physiologically active peptide having a very strong and continuous contraction to blood vessel and, because of that, its relation to diseases, particularly to cardiovascular diseases, has been discussed since the time when it was found.
Today, it is pointed out that there is a possibility that an excessive secretion of endothelin, particularly ET-1 (to be more specific, an increase in ET-1 concentration either topically or in tissues and circulating blood), participates not only in cardiovascular diseases but also in many other diseases. Thus, it was reported to participate, for example, in essential hypertension, pulmonary hypertension, hypertension induced by erythropoietin, hypertension induced by cyclosporin A, bronchial asthma, acute renal failure, chronic renal failure, glomerular nephritis, renal failure induced by cyclosporin, acute myocardial infarction, unstable angina, congestive heart failure, cerebrovascular spasm mostly after subarachnoid hemorrhage, cerebroischemic disturbance, urinary incontinence, benign prostatic hypertrophy, arteriosclerosis, Raynaud's syndrome, diabetic peripheral circulatory disturbance, diabetic renal diseases, preeclampsia, premature delivery, digestive ulcer, hepatic failure, rheumatism, restenosis after PTCA, chronic respiratory failure, chronic obstructive pulmonary diseases, cor pulmonale, acute respiratory failure, pulmonary edema, ischemic hepatic disturbance, adult respiratory distress syndrome, interstitial pneumonia, pulmonary fibrosis, glaucoma, osteoarthritis, chronic articular rheumatism, hepatic cirrhosis, inflammatory bowel diseases (IBD), cancer, etc. (G. M. Rubanyi, M. A. Plokoff, Pharmacological Reviews, vol. 46, no. 3, 325 (1994); Saishin Igaku, vol. 49, no.3, 335 (1994); Kidney International, 37, 1487-1491(1990); Lancet, 339, 381-385(1992); Cell Mol. Neurobiol., 13, 15-23 (1993); J. Clin. Encocrino. Metab., 76, 378-383 (1993); J. Clin. Pathol., 48(6), 519-524 (1995); Chest, 104(2), 476-480(1993); Am. J. Med., 99(3), 155-160 (1995); Hepatology, 16, 95-99 (1992); etc.).
Accordingly, pharmaceuticals which inhibit
REFERENCES:
Sakuma et al. JP 07061985, Caplus Abstract 1-2, 1995.
Douglas S. A. Clinical development of endothelin receptor antagonists. TIPS -Nov. 1997, 408-412.
Harada Hironori
Kazami Jun-ichi
Sudou Katsumi
Tanaka Akihiro
Tsuzuki Ryuji
Balasubramian V
Raymond Richard L.
Yamanouchi Pharmaceutical Co. Ltd.
LandOfFree
Arylethenesulfonamide derivatives and drug composition containin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylethenesulfonamide derivatives and drug composition containin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylethenesulfonamide derivatives and drug composition containin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1486857